{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:04:35Z","timestamp":1790024675331,"version":"4.0.1"},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,8,15]]},"DOI":"10.2169\/internalmedicine.0225-17","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T22:23:25Z","timestamp":1522362205000},"page":"2301-2313","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Characteristics, Phenotype of Lipodystrophy and a Genetic Analysis of Six Diabetic Japanese Women with Familial Partial Lipodystrophy in a Diabetic Outpatient Clinic"],"prefix":"10.2169","volume":"57","author":[{"given":"Masanori","family":"Iwanishi","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Kusatsu General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ito-Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Kusatsu General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Washiyama","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Kusatsu General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kusakabe","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Hypertension, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ebihara","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Jichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hussain I, Garg A. Lipodystrophy syndromes endocrinol. Metab Clin N Am 45: 783-797, 2016.","DOI":"10.1016\/j.ecl.2016.06.012"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndrome: a multi-society practice guideline. J Clin Endocrinol Metab 85: 1-14, 2016.","DOI":"10.1210\/jc.2016-2466"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Agarwal AK, Garg A. Genetic basis of lipodystrophies and management of metabolic complications. Annu Rev Med 57: 297-311, 2006.","DOI":"10.1146\/annurev.med.57.022605.114424"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 96: 3313-3325, 2011.","DOI":"10.1210\/jc.2011-1159"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Strickland LR, Lok K, Guo F, Garvey WT. Type 2 Diabetes with partial lipodystrophy of the limbs. Diabetes Care 36: 2247-2253, 2013.","DOI":"10.2337\/dc12-1529"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Demir T, Akinci B, Demir L, et al. Partial lipodystrophy of the limbs in a diabetes clinic setting. Prim Care Diabetes 10: 293-299, 2016.","DOI":"10.1016\/j.pcd.2015.12.006"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Guillin-Amarella C, Sanchez-Iglesias S, Castro-Pais A, et al. Type 1 familial partial lipodystrophy: understanding the Kobberling syndrome. Endocrine 54: 411-421, 2016.","DOI":"10.1007\/s12020-016-1002-x"},{"key":"8","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.metabol.2009.04.043","volume":"58","author":"M Iwanishi","year":"2009","unstructured":"8. Iwanishi M, Ebihara K, Kusakabe T, et al. Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy. Metabolism 58: 1681-1687, 2009.","journal-title":"Metabolism Clinical and Experimental","ISSN":"https:\/\/id.crossref.org\/issn\/0026-0495","issn-type":"print"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Iwanishi M, Ebihara K, Kusakabe T, et al. Premature atherosclerosis in a Japanese diabetic patient with atypical familial partial lipodystrophy and hypertriglyceridemia. Intern Med 51: 2573-2579, 2012.","DOI":"10.2169\/internalmedicine.51.7461"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Iwanishi M, Ebihara K, Kusakabe T, et al. A case of primary intestinal follicular lymphoma and premature atherosclerosis in a Japanese diabetic patient with atypical familial partial lipodystrophy. Intern Med 53: 851-858, 2014.","DOI":"10.2169\/internalmedicine.53.1713"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599, 2000.","DOI":"10.1161\/01.ATV.20.6.1595"},{"key":"12","unstructured":"12. Tokunaga K, Matsuzawa Y, Ishikawa K, Tarui S. A novel technique for the determination of body fat by computed tomography. Int J Obes 7: 437-445, 1983."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nakamura Y, Kikugawa S, Seki S, et al. PCSK5 mutation in a patient with the VACTERL association. BMC Res Notes 8: 228, 2015.","DOI":"10.1186\/s13104-015-1166-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Pinnick KE, Nicholson G, Manolopoulos N, et al. Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. Diabetes 63: 3785-3797, 2014.","DOI":"10.2337\/db14-0385"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Swarbrick MM. A lifetime on the hips: programming lower-body fat to protect against metabolic disease. Diabetes 83: 3575-3577, 2014.","DOI":"10.2337\/db14-1085"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet 49: 17-26, 2017.","DOI":"10.1038\/ng.3714"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yaghootkar H, Scott RA, White CC, et al. Genetic evidence for a normal-weight metabolically obese phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes 63: 4369-4377, 2014.","DOI":"10.2337\/db14-0318"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Scott RA, Fall T, Pasko D, et al; The RISC Study Group, The EPIC-InterAct Consortium. Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. Diabetes 63: 4378-4387, 2014.","DOI":"10.2337\/db14-0319"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Arioglu EA, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 133: 263-274, 2000.","DOI":"10.7326\/0003-4819-133-4-200008150-00009"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Oliveira J, Lau E, Carvalho D, Freitas P. Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystroohic syndromes: two case reports. J Med Case Rep 11: 12, 2017.","DOI":"10.1186\/s13256-016-1175-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kawara Y, Imai J, Sawada S, Yamada T, Katagiri H. Sodium-glucose cotransporter 2 inhibitors improves complications of lipodystrophy: a case report. Ann Intern Med 166: 450-451, 2017.","DOI":"10.7326\/L16-0372"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Haque WH, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophy. J Clin Endocrinol Metab 87: 2395-2398, 2002.","DOI":"10.1210\/jcem.87.5.8624"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Moon H-S, Dalamaga M, Kim S-Y, et al. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev 34: 377-412, 2013.","DOI":"10.1210\/er.2012-1053"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Chong AY, Lupsa BC, Gordon CP. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53: 27-35, 2010.","DOI":"10.1007\/s00125-009-1502-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ebihara K, Kusakabe T, Hirata M, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 92: 532-541, 2007.","DOI":"10.1210\/jc.2006-1546"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 85: 1776-1782, 2000.","DOI":"10.1210\/jcem.85.5.6605"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohpattis a meta-analysis. JAMA Intern Med 17: 633-640, 2017.","DOI":"10.1001\/jamainternmed.2016.9607"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Moon H-S, Dalamaga M, Kim S-Y, et al. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev 34: 377-412, 2013.","DOI":"10.1210\/er.2012-1053"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Dyck PJ, Windebank AJ. Diabetes and non diabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 25: 477-491, 2002.","DOI":"10.1002\/mus.10080"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Nicola C, Francesco B, Eleonora C, et al. Partial lipodystrophy associated with muscular dystrophy of unknown genetic origin. Muscle Nerve 49: 928-930, 2014.","DOI":"10.1002\/mus.24157"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Handelsman Y, Oral EA, Bloomgarden ZT, et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract 19: 107-116, 2013.","DOI":"10.4158\/endp.19.1.v767575m65p5mr06"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/16\/57_0225-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T18:13:34Z","timestamp":1570990414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/16\/57_0225-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,15]]},"references-count":31,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0225-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,15]]}}}